Rakuten Investment Management Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Rakuten Investment Management Inc. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,580 shares of the biopharmaceutical company’s stock after purchasing an additional 3,320 shares during the period. Rakuten Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $15,530,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $29,000. Trust Co. of Vermont bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $29,000. 83.31% of the stock is owned by institutional investors.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. Citigroup lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Canaccord Genuity Group cut their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Leerink Partners increased their price target on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research note on Monday, August 17th. Fifteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $800.36.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at approximately $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock valued at $1,090,030 over the last quarter. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $794.19 on Friday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The company has a market cap of $81.77 billion, a price-to-earnings ratio of 19.63, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. The stock has a fifty day simple moving average of $717.52 and a two-hundred day simple moving average of $718.38. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $12.81 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.